Ongoing Clinical Trials for Recurrent Liposarcoma
Currently, there is one ongoing clinical trial for recurrent liposarcoma. This trial is being conducted in Germany and evaluates a combination treatment approach for patients whose cancer has returned or has not responded to previous treatments. The study compares standard chemotherapy alone with a new combination therapy designed to improve treatment outcomes.
Clinical trial locations
Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment
This clinical trial investigates treatment options for patients with recurrent liposarcoma and other types of soft tissue sarcoma. The study compares two approaches: treatment with trabectedin alone, or trabectedin combined with an experimental drug called tTF-NGR. The main goal is to determine whether adding tTF-NGR to standard trabectedin treatment helps control the cancer for a longer period.
Who can participate:
The trial is open to adults between 18 and 75 years of age who have advanced or metastatic soft tissue sarcoma that has either not responded to previous anthracycline treatment or for whom anthracycline medications are not suitable due to medical reasons. Eligible participants must have confirmed high-grade soft tissue sarcoma, including several types of liposarcoma, as well as fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, synovial sarcoma, or undifferentiated sarcoma.
Participants must have at least one measurable tumor that has not been previously treated with radiation therapy, and their tumor must test positive for a specific protein marker called CD13. A life expectancy of at least three months is required, and participants must be able to carry out daily activities with an ECOG Performance Status of 2 or less.
Women who can become pregnant must have a negative pregnancy test and agree to use effective birth control during the study and for three months afterward. Men must use birth control methods for five months after their last treatment.
Who cannot participate:
The trial excludes individuals younger than 18 or older than 75 years of age. Patients without a confirmed diagnosis of soft tissue sarcoma or those who have not previously received anthracycline therapy are not eligible. Those who test negative for the CD13 protein marker cannot participate.
Women who are currently pregnant or breastfeeding are excluded from the study. Patients without measurable disease, those who have previously been treated with trabectedin, or those with severe heart, liver, or kidney problems cannot join the trial. Active uncontrolled infections, other active cancers requiring treatment, known allergic reactions to the study medications, inability to provide informed consent, or participation in another clinical trial within the past 30 days are also reasons for exclusion.
What the trial involves:
The study focuses on comparing the effectiveness of trabectedin alone versus trabectedin combined with tTF-NGR. Trabectedin is a chemotherapy medication that interferes with cancer cell growth and division. It is typically used when other treatments, particularly those containing anthracyclines, have not worked effectively.
The experimental drug tTF-NGR is designed to work together with trabectedin. It targets blood vessels in tumors and is intended to help trap the chemotherapy medication inside the tumor, making the treatment more effective by keeping the medication concentrated where it is needed most.
Both medications are administered through intravenous infusion directly into the bloodstream. Treatment can continue for up to 360 days, depending on how the cancer responds and whether any stopping criteria are met. Throughout the study, participants undergo regular medical examinations and imaging tests to monitor how their cancer responds to treatment.
The trial involves several steps: initial evaluation to confirm eligibility and test for CD13 positivity, random assignment to one of the two treatment groups, administration of the assigned treatment through intravenous infusion, regular monitoring during treatment with imaging tests and health assessments, and a follow-up period that includes continued health monitoring. The study is expected to continue until March 2029.
Summary
For patients with recurrent liposarcoma, there is currently one clinical trial available, located in Germany. This trial represents an important research effort to improve treatment options for patients whose cancer has returned or has not responded to standard therapies. The study investigates whether combining an experimental drug with standard chemotherapy can provide better disease control than chemotherapy alone. The trial specifically targets patients whose tumors have a particular characteristic (CD13 positivity), demonstrating a personalized medicine approach to treatment. Patients interested in participating should discuss with their healthcare provider whether they meet the eligibility criteria and whether this trial might be an appropriate option for their situation.
